Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an oral investigational drug candidate, Fostamatinib, for the treatment of chronic and persistent immune thrombocytopenia (ITP).

In ITP, the immune system attacks and destroys the body's own blood platelets, resulting in excessive bruising and bleeding.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Fostamatinib is designed to inhibit SYK kinase, a key component in the immune process that leads to platelet destruction in ITP. 

Rigel Pharmaceuticals president and chief executive officer Raul Rodriguez said: “This NDA submission in support of fostamatinib in ITP is a major milestone in bringing new treatment options to patients suffering from this disease.

“We look forward to working closely with the FDA as they review the submission over the coming months.”

"We look forward to working closely with the FDA as they review the submission over the coming months."

The NDA includes data from the Phase III clinical programme for Fostamatinib in both ITP and data procured from all studies, including preclinical evaluation and drug manufacturing data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This Phase III clinical programme evaluated 163 ITP patients and includes three studies, two randomised placebo-controlled studies (Studies 047 and 048) and an open-label extension study (Study 049).

In total, fostamatinib has been evaluated in more than 4,600 subjects across all indications.

Rigel expects to receive notification regarding the acceptance of the NDA from FDA by June this year.

FDA previously granted Orphan Drug designation to fostamatinib to treat ITP patients.